Short ‐Duration AL‐335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis

Conclusions: In treatment ‐naïve subjects without cirrhosis, AL‐335 + odalasvir + simeprevir for 6‐8 weeks was generally safe and highly efficacious against HCV GT1. However, inadequate efficacy was observed for the 2‐DAA regimen in GT1‐infected subjects and the 3‐DAA regimen in GT3‐infected subjects.

https://onlinelibrary.wiley.com/doi/abs/10.1002/hep.30126?af=R

Source: Hepatology - November 19, 2018 Category: Internal Medicine Authors: Edward J. Gane, Catherine A. Stedman, Christian Schwabe, Leen Vijgen, Sushmita Chanda, Thomas N. Kakuda, John Fry, Lawrence M. Blatt, Matthew W. McClure Tags: Original Article Source Type: research